CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM)

PHASE2CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

October 10, 2017

Primary Completion Date

April 21, 2020

Study Completion Date

April 21, 2020

Conditions
T2DM With Inadequate Glycemic Control
Interventions
DRUG

CS02 tablet and placebo tablet

Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.

Trial Locations (13)

114

Tri-Service General Hospital, Taipei

333

Chang Gung Memorial Hospital_Linkou, Taoyuan District

402

Chung Shan Medical University Hospital, Taichung

404

China Medical University Hospital, Taichung

710

Chi-Mei Medical Center, Tainan City

833

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

10048

National Taiwan University Hospital, Taipei

11217

Taipei Veterans general Hospital, Taipei

33016

The Community Research of South Florida, Hialeah

33134

Clinical Research of South Florida, Coral Gables

40705

Taichung Veterans General Hospital, Taichung

72212

Applied Research Center of Arkansas, Inc., Little Rock

81362

Kaohsiung Veterans General Hospital, Kaohsiung City

Sponsors
All Listed Sponsors
lead

Center Laboratories, Inc.

INDUSTRY